InspireMD (NYSE:NSPR) Insider Shane Thomas Gleason Sells 3,858 Shares

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 3,858 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $2.71, for a total transaction of $10,455.18. Following the completion of the sale, the insider directly owned 1,135,319 shares in the company, valued at $3,076,714.49. This represents a 0.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Trading Up 3.0%

Shares of NSPR stock traded up $0.03 during trading hours on Thursday, hitting $1.03. 160,140 shares of the company’s stock were exchanged, compared to its average volume of 182,457. The company has a market capitalization of $48.24 million, a PE ratio of -1.37 and a beta of 0.82. InspireMD, Inc. has a 12-month low of $0.97 and a 12-month high of $2.93. The business’s 50 day simple moving average is $1.40 and its 200-day simple moving average is $1.68.

Analyst Ratings Changes

Several research analysts have commented on NSPR shares. Maxim Group started coverage on shares of InspireMD in a research note on Monday, February 2nd. They set a “buy” rating and a $6.00 price target on the stock. Loop Capital set a $5.00 target price on shares of InspireMD in a report on Tuesday, February 24th. Piper Sandler restated an “overweight” rating and issued a $3.00 target price (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Finally, Lake Street Capital set a $4.00 target price on shares of InspireMD in a report on Monday, May 4th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $4.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NSPR. Creative Planning bought a new position in shares of InspireMD in the second quarter worth approximately $44,000. Raymond James Financial Inc. grew its holdings in shares of InspireMD by 28.9% in the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock worth $101,000 after purchasing an additional 10,000 shares during the last quarter. Rosalind Advisors Inc. grew its holdings in shares of InspireMD by 0.6% in the second quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company’s stock worth $5,196,000 after purchasing an additional 14,109 shares during the last quarter. Soleus Capital Management L.P. boosted its holdings in InspireMD by 99.5% in the second quarter. Soleus Capital Management L.P. now owns 1,886,207 shares of the company’s stock valued at $4,282,000 after acquiring an additional 940,831 shares in the last quarter. Finally, Courier Capital LLC boosted its holdings in InspireMD by 83.3% in the third quarter. Courier Capital LLC now owns 55,000 shares of the company’s stock valued at $133,000 after acquiring an additional 25,000 shares in the last quarter. Institutional investors own 44.78% of the company’s stock.

More InspireMD News

Here are the key news stories impacting InspireMD this week:

• Neutral Sentiment: Shane Thomas Gleason disclosed multiple recent sales of InspireMD shares, including transactions on May 19, May 23, May 27, May 29, May 30, and earlier January/February dates. Each filing says the sales were made to cover tax withholding obligations related to the vesting of equity awards, which makes the activity look more routine than a strategic exit. Article Title
• Neutral Sentiment: A new “Stock Forecast & Price Target” page for InspireMD may be contributing to increased trading interest, but the item itself does not include a specific rating change, earnings update, or business development that would clearly drive the shares. Article Title

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.